Tests a tau-targeting vaccine, alone or with donanemab, in early Alzheimer's
Tests AADvac1, alone or with donanemab, in adults with early Alzheimer's disease.
Plain-language title generated from the registry record
Registry title: Alzheimer's Tau Platform: Regimen A - AADvac1
Key facts
- Where
- Boston, Lexington, Nashville, Phoenix, Providence, San Francisco, and Seattle, United StatesSee the 7 sites
- Phase
- Phase 2
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 50 and 80 years old?
Source: NCT07167966, who can take part
Where in United States
- Brigham and Women's Hospital, Center for Alzheimer's Research and TreatmentBoston, United StatesNo longer taking part
- University of Kentucky Sanders Brown Center on AgingLexington, United StatesNo longer taking part
- Vanderbilt University Medical CenterNashville, United StatesNo longer taking part
- Banner Alzheimer's InstitutePhoenix, United StatesNo longer taking part
- Butler Hospital, Memory and Aging ProgramProvidence, United StatesNo longer taking part
- University of California, San Francisco (UCSF), Memory and Aging CenterSan Francisco, United StatesNo longer taking part
- Harborview Medical Center, University of WashingtonSeattle, United StatesNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Paul S. Aisen
- Trial code
- NCT07167966
- Record updated
- 26 October 2026
- Original description
The Alzheimer's Tau Platform (ATP) is a multi-center platform trial to evaluate the safety and effectiveness of tau-directed therapies, alone or in combination with donanemab, in adults aged 50-80 with late preclinical or early prodromal Alzheimer's disease.Read full original descriptionShow less
Alzheimer's Tau Platform (ATP): Regimen Specific Appendix for AADvac1
The Alzheimer's Tau Platform (ATP) is a multi-center platform trial to evaluate the safety and effectiveness of tau-directed therapies, alone or in combination with donanemab, in adults aged 50-80 with late preclinical or early prodromal Alzheimer's disease.
Regimen A will evaluate the safety and efficacy of AADvac1, alone or in combination with donanemab.
Inclusion: No additional inclusion criteria beyond the inclusion criteria specified in the Master Protocol (NCT06957418).
Exclusion: No additional exclusion criteria beyond the exclusion criteria specified in the Master Protocol (NCT06957418).